Shortage: Furosemide Oral Solution
This page indexes a United States Food and Drug Administration (FDA) drug-shortage record for Furosemide Oral Solution. The record is reported by Hikma Pharmaceuticals Usa, Inc. and currently carries a regulatory status of Current. A drug-shortage entry of this kind is an administrative supply-status record that the FDA maintains and publishes for transparency and reference. This entry names the affected product as Furosemide Oral Solution, attributes the report to the company shown above, and records a status of Current marking where the shortage sits within the agency's public tracking lifecycle at the time it was ingested by this site. The affected presentation is described in the source as Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63). The availability field published by the FDA reads: Limited Availability. This shortage record was published on 2026-06-11. It was first posted on 2026-03-31. All values shown here are reproduced as regulatory data points from the official FDA drug-shortages dataset to help you find and verify the original entry. This page does not advise on therapeutic substitution, does not assess clinical impact, and is not a recommendation of any kind. Verify the current status against the linked FDA source.
Source-derived regulatory summary
The text in this section is generated from the FDA source fields shown elsewhere on this page. It is regulatory information only — not medical advice — and adds no facts beyond the official record.
This record pertains to Furosemide Oral Solution, a medication presented in a concentration of 40 mg/5 mL, identified by NDC 0054-3298-63. The product is manufactured by Hikma Pharmaceuticals Usa, Inc. It is currently classified as having limited availability and is available on allocation. The initial posting date of this record is March 31, 2026, with the last update recorded on June 11, 2026.
Regulatory context
The status 'Current' indicates that the product is actively listed and available for regulatory purposes. 'Limited Availability' suggests that the product may not be widely accessible, and 'Available on allocation' means that distribution may be controlled or restricted based on specific criteria.
Fields used include generic_name, status, presentation, availability, company_name, related_info, initial_posting_date, and last_updated_date. No fields were absent.
FDA shortage data
| Generic name | Furosemide Oral Solution |
|---|---|
| Status | Current |
| Presentation | Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63) |
| Availability (source text) | Limited Availability |
| Reporting company | Hikma Pharmaceuticals Usa, Inc. |
| Related information | Available on allocation |
| Initial posting date | 2026-03-31 |
| Last updated date | 2026-06-11 |
How to interpret this shortage record
A drug-shortage record means the FDA has logged a reported supply constraint for a product as part of its public shortage tracking. The status (Current) describes where the shortage sits in its lifecycle according to the agency's data. A shortage entry is an administrative supply signal — it does not describe the clinical role of the product, does not suggest any substitute, and does not indicate that any specific patient is affected. Read this entry as a pointer to the official FDA shortage listing and confirm the live status there before relying on it.
What this record does not mean
This shortage record does not constitute medical advice and does not tell you whether to start, stop, switch, or avoid any product. It does not assess safety for any individual, does not provide dosage, treatment, or therapeutic guidance, and does not diagnose any condition. The dataset is coverage-limited: it reflects what the FDA has published in the indexed source at ingestion time, which may lag the live record and may omit details held only in primary documents. For any health decision, consult a qualified healthcare professional, and for the authoritative record consult the FDA directly through the linked official source.
Related manufacturer
This shortage is reported by Hikma Pharmaceuticals Usa Inc. That page aggregates the firm's other indexed records as coverage-limited regulatory signals (not quality ratings).
Related shortages (Current)
- Dexamethasone Sodium Phosphate Injection · 2026-06-11
- Midazolam Hydrochloride Injection · 2026-06-11
- Lorazepam Injection · 2026-06-11
- Midazolam Hydrochloride Injection · 2026-06-11
- Promethazine Hydrochloride Injection · 2026-06-11
Source & provenance
- Official source
- https://www.accessdata.fda.gov/scripts/drugshortages/
- Source dataset
- openFDA Drug Shortages API
- Publication date
- 2026-03-31
- Ingested
- 2026-06-13
- Record hash
4999d1f8e3a9de60
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.